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Background: Narrow band imaging (NBI) is an optical enhancement technology that
filters white light into two bandwidths of illumination centered on 415 nm (blue) and
540 nm (green). NBI cystoscopy can increase bladder cancer (BCa) visualization and
detection at the time of transurethral resection (TUR). NBI may therefore reduce
subsequent relapse following TUR.
Objective: Assess the impact of NBI modality on 1-yr non–muscle-invasive BCa (NMIBC)
recurrence risk.
Design, setting, and participants: Consecutive patients with overt or suspected BCa
were included in a prospective study powered to test a 10% difference in 1-yr recurrence
risk in favor of cases submitted to NBI TUR. Excluding patients with muscle-invasive BCa,
negative pathologic examination, or without follow-up, the study population was
composed of 148 subjects randomized from August 2009 to September 2010 to NBI
TUR (76 cases) or white light (WL) TUR (72 cases).
Intervention: TUR was performed in NBI or standard WL modality.
Measurements: The 1-yr recurrence risks in NBI or WL TUR groups were compared
using odds ratio (OR) point and interval estimates derived from logistic regression
modeling.
Results and limitations: The 1-yr recurrence-risk was 25 of 76 patients (32.9%) in the
NBI and 37 of 72 patients (51.4%) in the WL group (OR = 0.62; p = 0.0141). Simple and
multiple logistic regression analyses provided similar OR points and interval estimates.
Conclusions: TUR performed in the NBI modality reduces the recurrence risk of NMIBC
by at least 10% at 1 yr.
# 2012 Published by Elsevier B.V. on behalf of European Association of Urology.
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Narrow band imaging (NBI) is an optical enhancement
technology that increases the contrast between vasculaturePlease cite this article in press as: Naselli A, et al. A Randomized Pr
in Narrow Band Imaging Modality on Non–Muscle-Invasive 
j.eururo.2012.01.018
0302-2838/$ – see back matter # 2012 Published by Elsevier B.V. on behalfand superficial tissue structures of the mucosa [1]. It
consists of two bandwidths of illumination centered on
415 nm, blue, and 540 nm, green. In the NBI mode, light is
absorbed strongly by hemoglobin and penetrates only theospective Trial to Assess the Impact of Transurethral Resection
Bladder Cancer Recurrence. Eur Urol (2012), doi:10.1016/
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EURURO 4328 1–6uperficial layers of the tissue increasing the visibility of
apillaries and superficial tissue structures. Since its
ntroduction in the endoscopic systems, the use of NBI
as spread rapidly. Regarding bladder cancer (BCa), NBI is
nown to increase the detection rate in prospective within-
ubject studies in which the bladder is examined sequen-
ially in standard and NBI modality [2–4] even by different
bservers [5]. Most importantly, nonrandomized studies
videnced an impact of the examination of the bladder in
BI modality while performing transurethral resection
TUR) or follow-up cystoscopy on recurrence probability of
on–muscle-invasive BCa (NMIBC) [6,7]. We performed a
rospective randomized trial to assess the impact of TUR
erformed in NBI modality on NMIBC recurrence risk.
. Patient and methods
ll patients were adults; women who were pregnant, breastfeeding, or
ot on adequate contraceptive measures were excluded. All patients
rovided a written informed consent prior to the study. The study was
onducted in accordance with good clinical practice and the 1964
eclaration of Helsinki, including the most recent amendments
Edinburgh, Scotland, 2000), and after written approval of the local
edical ethical committee. The trial was registered and the identifier
CT01004211 assigned.
.1. Patient selection
onsecutive patients from two centers in Liguria (IST, Genova, and
entro Urologico di Eccellenza ASL 1, Imperia) with overt or suspected
Ca were included in the study and randomized to two treatments arms,
tandard white light (WL) TUR and NBI TUR, respectively.
TUR was carried out entirely in the WL or in the NBI mode
introduction of the resectoscope, preliminary cystoscopy, tumor
esection, coagulation). A switch from standard to NBI mode or vice
ersa during the procedure was not allowed.
Indication for TUR or adjuvant intravesical therapy was given on the
asis of the AURO.it Guideline Committee on BCa 2008 [8]. Accordingly,
o patient was submitted to immediate postoperative intravesical
ladder instillation of any chemotherapeutic agent.
Randomization was centralized and performed by means of a
andom table. All surgeons involved in the study were trained to use the
BI modality. Patients were submitted to WL or NBI TUR and/or cold cup
iopsies of all visible lesions known or suspected to be BCa. A second TUR
as performed in the same modality (WL or NBI) in case of newly
iagnosed high-grade NMIBC or of grossly incomplete resection or of
bsence of muscle in the specimen and was considered part of the same
ndoscopic procedure in regard to the trial.
Six random cold cup biopsies from healthy mucosa of bladder
rigone, anterior, posterior, and lateral walls were taken in case of a
econd TUR of newly diagnosed/recurrent high-grade NMIBC or in case
f positive urinary cytology and negative standard office cystoscopy.
.2. Exclusion criteria
atients with invasive BCa or absence of urothelial cancer after
athologic examination or without follow-up were excluded.
.3. Pathologic examination
he specimen of each lesion was analyzed individually by a pathologist
linded to the mode of identification of the single lesion (WL or NBI).Please cite this article in press as: Naselli A, et al. A Randomized 
in Narrow Band Imaging Modality on Non–Muscle-Invasive
j.eururo.2012.01.018Staging was given in accordance with the TNM classification (2002
Union Internationale Contre le Cancer) and grading by the World Health
Organization 2004 classification. Patients with pure carcinoma in situ
(CIS) were grouped as having high-grade cancer.
2.4. End points
The primary end point was the 1-yr intravesical recurrence risk. Recurrence
was defined as positive findings on cystoscopy or on urine cytology that
had to be confirmed histologically. Only patients diagnosed with pure CIS
were considered at risk of a recurrence in case of consecutive positive
findings on cytology even in the absence of histologic confirmation. The
secondary end points were 3-mo recurrence risk and the detection rate.
2.5. Follow-up scheme
Follow-up was conducted in the standard WL mode to assess uniformly
the main end point of the study. Three months after the endoscopic
treatment, a urinary cytology (in cases of high-grade BCa) and a cystoscopy
were performed given their great prognostic impact [9]. Thereafter
patients with high-grade cancer were monitored with urinary cytology
and cystoscopy every 3 mo and computed tomography (CT) scan
urography every year. Patients with low-grade cancer at high risk of
recurrence (namely newly diagnosed multiple or newly diagnosed single
low-grade NMIBC >3 cm or any recurrent low-grade NMIBC) were
monitored with cystoscopy every 6 mo and with CT scan urography yearly
(only if highly recurrent). Patients with low-grade cancer at low risk of
recurrence (newly diagnosed single low-grade NMIBC <3 cm) were
monitored with a urinary cytology and cystoscopy after 9 mo and yearly
thereafter [8]. Thus recurrence status of all patients included was available
at 3 and 12 mo.
2.6. Study design and statistical analysis
It is estimated that the proportion of lesions detected is increased by
approximately 20% using NBI compared with WL cystoscopy [2,3,10].
We hypothesized that such a rise in detection rate could be translated
into a reduction of the relapse probability. Therefore, we assumed a 1-yr
recurrence risk of 50% in the WL TUR group and of 40% in the NBI TUR
group. To appreciate statistically such a difference (D = 10%), consid-
ering a power of 80%, a two-tailed significance level of 5%, and a lost to
follow-up proportion of 10%, we calculated a sample size of 85 patients
per study group, 170 total, by using the Cohen formula [11].
Potential imbalances by TUR techniques in patients’ background
factors (ie, age and year of enrollment, gender, clinical status, multifocal
tumor, grading, staging, and adjuvant therapy regimen) were statisti-
cally evaluated using the chi-square test or, whenever useful, the Fisher
exact test. The chi-square test was also applied to evaluate the difference
between the two 1-yr recurrence risks (primary end point). Finally,
logistic regression analysis [12] was applied to model the recurrence
probabilities, and, accordingly, the odds ratio (OR) was used as an index
of relative risk (RR) of recurrence (NBI vs WL). Simple and multiple
regression analyses were performed to evaluate the effect of patients’
background characteristics on the study relationships [13]. For each OR,
95% confidence limits (95% CIs) were also computed.
All tests were two tailed, and statistical significance was considered
achieved if p value < 0.05. Data were analyzed using Stata software
v.11.2 (StataCorp, College Station, TX, USA).
3. Results
A total of 223 patients scheduled for TUR from August 2009
to September 2010 were assessed for eligibility. Of these, 9Prospective Trial to Assess the Impact of Transurethral Resection
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EURURO 4328 1–6declined participation and 26 consented to another study.
Thus 188 were randomized to standard (93 patients) or NBI
(95 patients) TUR. After obtaining histologic examination,
24 were excluded for invasive disease (T2 or more), 8 for
absence of disease, and 1 for the diagnosis of endometriosis,
leaving 76 patients in the standard group and 79 in the NBI
group. Four patients in the standard group and three
patients in the NBI group did not relapse and did not reach
1-yr follow-up, and therefore they were excluded from the
analysis. Finally, 72 and 76 patients in the standard and NBI
group remained for the final analysis as reported in the
Consolidated Standards of Reporting Trials diagram (Fig. 1).
Clinical and pathologic characteristics were balanced
among the two groups (Table 1). A second TUR was
performed in 39 cases (26%): 36 cases had a newly
diagnosed Ta/T1 high-grade cancer, one case had a grossly
incomplete resection of a voluminous tumor, and one case
was found without muscle tissue in the specimen. Overall
the BCa detection rate (a secondary end point) was 1.36
lesions per person in the WL group and 1.55 per person in
the NBI group ( p = 0.07). The incidence of false-positive
findings was 46 of 164 (28%) and 26 of 124 (21%) in the NBI
and in the standard group, respectively (RR: 1.34; 95% CI,
0.86–2.11; p = 0.217). Median follow-up was 11 mo (range:
2–19 mo). Follow-up ended due to recurrence in 61 cases
(41.2%). Recurrences were histologically confirmed in all
cases, but two had a pure CIS and positive consecutive
findings on urinary cytology. The 3-mo and 1-yr recurrence
risks were 15 of 148 (10.1%) and 61 of 148 (41.2%),
respectively. The respective figures were 12 of 72 (16.7%)




Excluded from the analysis: 0 
Received standard TUR: 93 
Discontinued follo w-up in 17 for diagnosis of 
T2: 13 
T0: 3 
Endom etriosis:  1 
Lost at follow-up : 4 (3 did  not reac h 1-yr 
follow-u p; 1 died of u nre lated causes 2 mo 
after TUR) 
Fig. 1 – Consolidated Standards o
NBI = narrow band imaging; TUR
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j.eururo.2012.01.01824 of 76 (31.6%) in the NBI group. Accordingly, 1-yr risk
difference (primary end point) results were approximately
20% in favor of the NBI group (D = 19.8; 95% CI, 34.4 to
4.2; p = 0.0141). A discernable risk reduction was also
observed after 3 mo of follow-up (secondary end point).
However, in this case the NBI group showed an appreciably
lower absolute advantage of almost 13% (D = 12.8; 95% CI,
22.4 to 3.1; p = 0.0084) (Table 2). Comparison between
simple and multiple logistic regression results did not show
any substantial difference in OR point and interval
estimates (Table 2). Ultimately, NBI technique reduced
the 1-yr and 3-mo relapse probability of almost 40% (OR:
0.62; 95% CI, 0.4–0.92) and 75% (OR: 0.24; 95% CI,
0.07–0.81), respectively (Table 1).
4. Discussion
Evidence shows that NBI increases the detection of BCa
[2–5]. We hypothesized this would reduce subsequent
recurrence by removing cancers overlooked by WL
cystoscopy. To date, two reports have looked at the impact
of NBI on recurrence risk [6,7]. In the first, 126 patients with
recurrent BCa were followed from 2003 to 2006 with
standard cystoscopy and from 2006 to 2009 with NBI
cystoscopy. The median (95% CI) recurrence-free survival
time on standard surveillance was 13 mo (range: 11.6–14)
compared with 29 mo (range: 26–32) on NBI cystoscopy
( p = 0.001) [6]. This study had several limitations. For
example, the cohorts were not randomized, and the same
surgeon performed WLC and NBI, allowing a potential
‘‘second-look’’ bias [6]. In the second study, 118 patientsty:  22 3
Excl uded:  35  
Declined to  pa rticipat e: 9 
Enro llment in anot her study: 26 
Received  NB I TU R: 95  
Discontin ued follo w-up in 16  for diagnos is of 
T2: 11 
T0: 5 
Lost at follow-up: 3 (3 did not r each 1-yr 
follow-up ) 
Analyz ed: 76 
Exclu ded from the analysis: 0 
f Reporting Trials diagram.
 = transurethral resection.
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Table 1 – Population characteristics (white light group vs narrow
band imaging group)
Variables TUR p value
WL NBI
Age 0.694








Hospital 1 10 15
Hospital 2 62 61
Clinical status 0.230
Recurrent 28 37














3 cm 53 55
>3 cm 19 21
Adjuvant topical therapy 0.166
No therapy 49 42
BCG 19 24
Mitomycin 4 10
Whole sample (%) 72 (48.7) 76 (51.3) –
BCG = bacillus Calmette-Guérin; CIS = carcinoma in situ; NBI = narrow
band imaging; p value: significance level of chi-square or Fisher exact
test; SD = standard deviation; TUR = transurethral resection; WL = white
light.
* Includes patients with pure or associated CIS.
** Includes patients with pure CIS.
Table 2 – Results of logistic regression analyses of 1-yr and 3-mo re
Time to recurrence TUR 
WL NBI 
No. (%) No. (%) 
1 yr 37 (51.4) 24 (31.6) 
3 mo 12 (16.7) 3 (3.9) 
Whole sample 72 (100.0) 76 (100.0)
TUR = transurethral resection; D = absolute difference in recurrence risks; D
recurrence; WL = white light; NBI = narrow band imaging; 95% CI = 95% confid
Note: Simple/Multiple: OR point and interval estimates unadjusted/adjusted fo
clinical status, multifocal tumor, grading, staging, and adjuvant therapy regim
E U R O P E A N U R O L O G Y X X X ( 2 0 1 2 ) X X X – X X X4
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j.eururo.2012.01.018submitted to standard TUR/bladder biopsies were retro-
spectively selected and a group of 40 patients were
prospectively enrolled in a NBI TUR/bladder biopsies
program [7]. The end point was patient status at 3 mo.
Residual tumor was detected in 36 of 118 patients (30.5%)
treated by standard TUR and 6 of 40 patients (15.0%)
treated by NBI TUR, thus an absolute difference in 3-mo
residual/recurrent cancer risk of 15.5% in favor of NBI TUR
( p = 0.04). The result was confirmed in a logistic regression
model showing that the probability of finding residual/
recurrence tumor at 3 mo was significantly higher in
patients previously submitted to standard TUR (OR: 2.7;
95% CI, 1.2–6.1; one-sided p value = 0.03) [7].
Fluorescence cystoscopy is a well-established procedure
that increases BCa detection rate similarly to NBI [14–17].
The impact of fluorescence TUR on the recurrence rate of
NMIBC in well-designed prospective randomized studies is
not yet clear [14–17].
A study including 416 patients, randomly assigned to WL
TUR, fluorescence TUR with 5-aminolevulinic acid, and
fluorescence TUR with hexaminolevulinate showed a
benefit of about 10% in terms of lower 3-yr recurrence risk
for the fluorescence TUR [14]. In a cohort of 115 patients
randomly submitted to WL or fluorescence TUR, fluores-
cence TUR improved the recurrence-free risk of about 20%
within the first year of follow-up [15]. Two subsequent
randomized studies failed to confirm the ability of
fluorescence cystoscopy to decrease the recurrence risk
[16,17].
Unfortunately, to date no comparison study between NBI
and fluorescence cystoscopy has been performed, and, apart
from ours, there is only one other ongoing prospective study
from the Clinical Research Office of the Endourological
Society [18] to assess the impact of NBI on recurrence risk.
In a previous paper we showed that TUR in the NBI
modality is feasible [19]. The study was designed to disclose
a 10% absolute risk difference in favor of the group treated
with the NBI modality. The actual 1-yr difference was about
20%, and, most importantly, the objective was reached with
the use of NBI, a minimal technical modification to thecurrence risks
Simple Multiple
D (D%) OR OR
(95% CI) (95% CL) (95% CI)
p value p value
19.8 (38.5) 0.62 0.57
(4.2 to 35.4) (0.41–0.92) (0.38–0.85)
0.0141 0.0053
12.8 (76.7) 0.24 0.26
(22.4 to 3.1) (0.07–0.81) (0.07–0.75)
0.0084 0.0090
% = relative difference in recurrence risks; OR = odds ratio, relative risk of
ence limits for D or OR; p value = significance level.
r background patients’ characteristics (ie, age and year of enrollment, gender,
en).
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EURURO 4328 1–6standard TUR. The main limitation of our study was that
surgeons could not be blinded to the modality used.
The 3-mo recurrence risk, a secondary end point, was
3.9% and 16.7% in the NBI and WL group, respectively. The
early recurrence risk is lower than usual [9] and, to our
knowledge, it can only be explained by the increased
detection that avoids recurrences due to overlooked
tumors.
Accordingly, the detection rate, another secondary end
point of the study, was increased in the NBI group (1.36
lesions per person in the WL group, 1.55 in the NBI group;
p = 0.07). However, it corresponds to a slight increase in the
incidence of false-positive findings that was 46 of 164 (28%)
and 26 of 124 (21%) in the NBI and in the standard group,
respectively (RR: 1.34; 95% CI, 0.86–2.11; p = 0.217).
However, it does not seem clinically relevant inasmuch
as it translates as less than one additional biopsy/resection
for a suspected lesion for every 10 performed in a patient
who should undergo TUR anyway.
It should be noted that although the recurrence
probability increased in the NBI group during the study
from 4% at 3 mo to 32% at 1 yr, it increased from 12% to 51%
in the standard group. A possible explanation for the higher
tendency toward increment of recurrence frequency may be
that some recurrences are explained by causes other than
missed tumors such as the ‘‘field cancerization’’ effect [20]
or the ‘‘clonality’’ origin of urothelial cancer [21] that are not
yet completely understood.
5. Conclusions
TUR performed in NBI modality reduces the 1-yr recurrence
risk of NMIBC by at least 10%.
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